Fig. 6: Pharmacokinetics of Cpd1 in mice.

a Averaged plasma concentration–time profiles of Cpd1 following i.p. injection of 3 mg/kg and 10 mg/kg. Data are means ± SD (n = 6 per time point in each group). b Metabolic stability of Cpd1 in the presence of mouse or human liver microsomes. Residual rates of Cpd1 at 0 min were considered 100%. Data are means ± SD (mouse: n = 7; human; n = 4) and were analyzed by two-tailed unpaired t-test. c Effect of Cpd1 on muscle force of WT mice in vivo. Muscle force was measured by grip force test (4-grips test). The tests were performed before (pre) and 10 and 60 min after i.p. injection of saline (n = 14) or Cpd1 (n = 14). The force values were normalized by body weight (BW). Data are shown as means ± SD and were analyzed by one-way ANOVA with Tukey’s test. d–f Effect of repeated administration of Cpd1 on rectal temperature of R2509C mice stimulated by isoflurane (d) or environmental heat stress (e). Cpd1 was i.p. injected 8 times at 1 mg/kg every 10 min and stimulus (isoflurane or environmental heat) was started at time 0. f Survival rate of mice 90 min after isoflurane or heat stress challenge. All the mice survived. g Averaged plasma concentration–time profiles of Cpd1 following 8-times injection of 1 mg/kg at 10 min intervals in male and female mice. Data are shown as means ± SD (n = 3 per time point). h Effect of Cpd1 on muscle force of male (n = 3) and female (n = 3) WT mice in vivo following 8-times injection of 1 mg/kg at 10 min intervals. Data are shown as means ± SD and were analyzed by one-way ANOVA with Tukey’s test. Source data are provided as a Source Data file.